Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:associatedWith |
gptkb:tetrabenazine
|
| gptkbp:ATCCode |
N07XX11
|
| gptkbp:CASNumber |
1392826-25-3
|
| gptkbp:chemicalFormula |
C19H19D6NO3
|
| gptkbp:contraindication |
hepatic impairment
use with MAO inhibitors use with reserpine |
| gptkbp:drugClass |
vesicular monoamine transporter 2 (VMAT2) inhibitor
|
| gptkbp:genericName |
gptkb:deutetrabenazine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Austedo
|
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Teva_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
VMAT2 inhibition
|
| gptkbp:pregnancyCategory |
Not assigned (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
anxiety fatigue insomnia somnolence |
| gptkbp:usedFor |
tardive dyskinesia
chorea associated with Huntington's disease |
| gptkbp:bfsParent |
gptkb:Teva_Pharmaceutical_Industries
|
| gptkbp:bfsLayer |
5
|